发布求助
文献互助 智能选刊 最新文献

Blood Reviews最新文献

筛选
英文 中文
Continuing progress in radioimmunotherapy for hematologic malignancies 恶性血液病放射免疫治疗的持续进展。
IF 6.9 2区 医学
Blood Reviews Pub Date : 2025-01-01 DOI: 10.1016/j.blre.2024.101250
Hiroki Goto , Yoshioki Shiraishi , Seiji Okada
{"title":"Continuing progress in radioimmunotherapy for hematologic malignancies","authors":"Hiroki Goto ,&nbsp;Yoshioki Shiraishi ,&nbsp;Seiji Okada","doi":"10.1016/j.blre.2024.101250","DOIUrl":"10.1016/j.blre.2024.101250","url":null,"abstract":"<div><div>Radioimmunotherapy (RIT) involves combining a cytotoxic radionuclide with an antibody (Ab) targeting a tumor antigen. Compared with conventional therapies, RIT improves the therapeutic efficacy of Ab and ameliorates toxicity. This comprehensive review describes the current advancements and future prospects in RIT for treating hematologic malignancies based on recent investigations. Although β-particle RITs targeting CD20 are effective with low toxicity in patients with relapsed/refractory indolent or transformed non-Hodgkin's lymphoma, these treatments have not gained popularity because of the increasing availability of new therapies. RIT using single-domain antibodies is expected to improve tumor penetrance and reduce radiation exposure to non-target organs. To enhance RIT efficacy, α-particle RIT and pretargeted radioimmunotherapy (PRIT) are currently being developed. Alpha-particle RIT demonstrates substantial antitumor activity and reduced bystander effects due to its high linear energy transfer and short particle range. PRIT may increase the tumor-to-whole body dose ratio.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"69 ","pages":"Article 101250"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142752539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Point-of-care diagnostic test accuracy in children and adolescents with sickle cell disease: A systematic review and meta-analysis 儿童和青少年镰状细胞病的即时诊断测试准确性：一项系统回顾和荟萃分析
IF 6.9 2区 医学
Blood Reviews Pub Date : 2025-01-01 DOI: 10.1016/j.blre.2024.101243
Robert Bagnall , Danielle Guy , Rebecca L. Morgan , Ifeoluwa Babatunde , Agathe Nevière , Gabriela Friedrich , Liga Bennetts , Omar Irfan , Isaac Odame
{"title":"Point-of-care diagnostic test accuracy in children and adolescents with sickle cell disease: A systematic review and meta-analysis","authors":"Robert Bagnall ,&nbsp;Danielle Guy ,&nbsp;Rebecca L. Morgan ,&nbsp;Ifeoluwa Babatunde ,&nbsp;Agathe Nevière ,&nbsp;Gabriela Friedrich ,&nbsp;Liga Bennetts ,&nbsp;Omar Irfan ,&nbsp;Isaac Odame","doi":"10.1016/j.blre.2024.101243","DOIUrl":"10.1016/j.blre.2024.101243","url":null,"abstract":"<div><h3>Background</h3><div>Detection of sickle cell disease (SCD) could be improved with greater use of point-of-care testing (POCT). This review assessed the accuracy of POCTs for SCD in children and adolescents.</div></div><div><h3>Methods</h3><div>We systematically searched EMBASE, PubMed, Cochrane libraries, registries and conference proceedings from inception to 28th February 2023. We included cross-sectional and case-control studies that tested for SCD using POCTs and reference tests in individuals aged 0–19. We conducted meta-analysis to assess sensitivity and specificity of individual POCTs.</div></div><div><h3>Findings</h3><div>The review included 31 studies overall, with 20 covering lateral flow immunoassays (LFIAs) and four covering micro-engineered electrophoresis. When detecting homozygous SCD, the pooled sensitivity and specificity of the included LFIAs and micro-engineered electrophoresis POCTs was 92 % or higher in all individual meta-analyses. Sensitivities and specificities were also nearly 100 % when detecting haemoglobin SC disease for these POCTs.</div></div><div><h3>Interpretation</h3><div>POCTs could be used to accurately diagnose SCD.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"69 ","pages":"Article 101243"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142756026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neuro-toxicities of chemo- and immune-therapies in haematologic malignancies: from mechanism to management 血液恶性肿瘤化疗和免疫疗法的神经毒性：从机制到管理。
IF 6.9 2区 医学
Blood Reviews Pub Date : 2025-01-01 DOI: 10.1016/j.blre.2024.101254
David Kegyes , Vlad Moisoiu , Catalin Constantinescu , Alina Tanase , Gabriel Ghiaur , Hermann Einsele , Ciprian Tomuleasa , Hillard M. Lazarus , Robert Peter Gale
{"title":"Neuro-toxicities of chemo- and immune-therapies in haematologic malignancies: from mechanism to management","authors":"David Kegyes ,&nbsp;Vlad Moisoiu ,&nbsp;Catalin Constantinescu ,&nbsp;Alina Tanase ,&nbsp;Gabriel Ghiaur ,&nbsp;Hermann Einsele ,&nbsp;Ciprian Tomuleasa ,&nbsp;Hillard M. Lazarus ,&nbsp;Robert Peter Gale","doi":"10.1016/j.blre.2024.101254","DOIUrl":"10.1016/j.blre.2024.101254","url":null,"abstract":"<div><div>Chemo- and immune therapies administered to treat haematologic malignancies frequently cause neurologic injury. The adverse events range from mild cognitive impairment and headaches to severe conditions such as seizures, stroke and encephalitis. We performed a comprehensive literature review and report the types, mechanisms, management and prevention of neuro-toxicity resulting from these therapies in subjects who develop these toxic effects. Our paper will not discuss radiation therapy, as it has already been extensively reviewed by many authors. Our focus will be on recently developed anti-cancer drugs.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"69 ","pages":"Article 101254"},"PeriodicalIF":6.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Host-directed therapies modulating innate immunity against infection in hematologic malignancies. 宿主导向疗法调节先天免疫对抗血液恶性肿瘤感染。
IF 6.9 2区 医学
Blood Reviews Pub Date : 2024-12-13 DOI: 10.1016/j.blre.2024.101255
Qiong Wang, Kristján Hermannsson, Egill Másson, Peter Bergman, Guðmundur Hrafn Guðmundsson
{"title":"Host-directed therapies modulating innate immunity against infection in hematologic malignancies.","authors":"Qiong Wang, Kristján Hermannsson, Egill Másson, Peter Bergman, Guðmundur Hrafn Guðmundsson","doi":"10.1016/j.blre.2024.101255","DOIUrl":"https://doi.org/10.1016/j.blre.2024.101255","url":null,"abstract":"<p><p>Patients with hematologic malignancies (HM) are highly susceptible to bloodstream infection (BSI), particularly those undergoing treatments such as chemotherapy. A common and debilitating side effect of chemotherapy is oral and intestinal mucositis. These Patients are also at high risk of developing sepsis, which can arise from mucosal barrier injuries and significantly increases mortality in these patients. While conventional antibiotics are effective, their use can lead to antimicrobial resistance (AMR) and disrupt the gut microbiota (dysbiosis). In this review, we discuss utilizing host defense peptides (HDPs), key components of the innate immune system, and immune system inducers (ISIs) to maintain mucosal barrier integrity against infection, an underexplored host-directed therapy (HDT) approach to prevent BSI and sepsis. We advocate for the discovery of potent and safe ISIs for clinical use and call for further research into the mechanisms by which these ISIs induce HDPs and strengthen mucosal barriers.</p>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":" ","pages":"101255"},"PeriodicalIF":6.9,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Absolute and functional iron deficiency: Biomarkers, impact on immune system, and therapy 绝对性和功能性缺铁：生物标志物、对免疫系统的影响和治疗。
IF 6.9 2区 医学
Blood Reviews Pub Date : 2024-11-01 DOI: 10.1016/j.blre.2024.101227
Marianela Iriarte-Gahete , Laura Tarancon-Diez , Vanesa Garrido-Rodríguez , Manuel Leal , Yolanda María Pacheco
{"title":"Absolute and functional iron deficiency: Biomarkers, impact on immune system, and therapy","authors":"Marianela Iriarte-Gahete ,&nbsp;Laura Tarancon-Diez ,&nbsp;Vanesa Garrido-Rodríguez ,&nbsp;Manuel Leal ,&nbsp;Yolanda María Pacheco","doi":"10.1016/j.blre.2024.101227","DOIUrl":"10.1016/j.blre.2024.101227","url":null,"abstract":"<div><div>Iron is essential for numerous physiological processes and its deficiency often leads to anemia. Iron deficiency (ID) is a global problem, primarily affecting reproductive-age women and children, especially in developing countries. Diagnosis uses classical biomarkers like ferritin or transferrin saturation. Recent advancements include using soluble transferrin receptor (sTfR) or hepcidin for improved detection and classification of absolute and functional iron deficiencies, though mostly used in research. ID without anemia may present symptoms like asthenia and fatigue, even without relevant clinical consequences. ID impacts not only red-blood cells but also immune system cells, highlighting its importance in global health and immune-related comorbidities. Managing ID, requires addressing its cause and selecting appropriate iron supplementation. Various improved oral and intravenous products are available, but further research is needed to refine treatment strategies. This review updates on absolute and functional iron deficiencies, their relationships with the immune system and advancements in diagnosis and therapies.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"68 ","pages":"Article 101227"},"PeriodicalIF":6.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141984022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breaking down frailty: Assessing vulnerability in acute myeloid leukemia 打破虚弱：评估急性髓性白血病的脆弱性
IF 6.9 2区 医学
Blood Reviews Pub Date : 2024-11-01 DOI: 10.1016/j.blre.2024.101224
Lacey S. Williams , Teja Nagaradona , Prathik Nalamalapu , Catherine Lai
{"title":"Breaking down frailty: Assessing vulnerability in acute myeloid leukemia","authors":"Lacey S. Williams ,&nbsp;Teja Nagaradona ,&nbsp;Prathik Nalamalapu ,&nbsp;Catherine Lai","doi":"10.1016/j.blre.2024.101224","DOIUrl":"10.1016/j.blre.2024.101224","url":null,"abstract":"<div><div>Acute myeloid leukemia (AML) is a disease primarily affecting older adults. However, not all patients at older ages are suitable for curative treatment with intensive chemotherapy due to “frailty” demonstrated by their functional status, physiologic reserve, and vulnerability to disease and treatment morbidity. Lack of consensus exists on how to select older, less fit patients most appropriate for standard intensive chemotherapy (IC), hypomethylating agents (HMA) with venetoclax, or less intensive regimens. A total of 37 studies of frailty assessments and composite indices in AML show heterogeneous results regarding the ability of frailty and Comprehensive Geriatric Assessment (CGA) measures to predict treatment outcomes. CGA, Geriatric 8 (G8) risk score, and hematopoietic cell transplant comorbidity index (HCT-CI) show association with prognosis, and should be validated in larger therapeutic trials. Studies of biomarkers, like albumin and C-reactive protein, and patient-reported outcomes demonstrate the potential to enhance information gained from rigorous geriatric assessment.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"68 ","pages":"Article 101224"},"PeriodicalIF":6.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141847614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways? 血液肿瘤中的可测量残留疾病（MRD）检测：大跃进还是走弯路？
IF 6.9 2区 医学
Blood Reviews Pub Date : 2024-11-01 DOI: 10.1016/j.blre.2024.101226
Qiujin Shen , Xiaowen Gong , Yahui Feng , Yu Hu , Tiantian Wang , Wen Yan , Wei Zhang , Saibing Qi , Robert Peter Gale , Junren Chen
{"title":"Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?","authors":"Qiujin Shen ,&nbsp;Xiaowen Gong ,&nbsp;Yahui Feng ,&nbsp;Yu Hu ,&nbsp;Tiantian Wang ,&nbsp;Wen Yan ,&nbsp;Wei Zhang ,&nbsp;Saibing Qi ,&nbsp;Robert Peter Gale ,&nbsp;Junren Chen","doi":"10.1016/j.blre.2024.101226","DOIUrl":"10.1016/j.blre.2024.101226","url":null,"abstract":"<div><div>Measurable residual disease (MRD)-testing is used in many haematological cancers to estimate relapse risk and to direct therapy. Sometimes MRD-test results are used for regulatory approval. However, some people including regulators wrongfully believe results of MRD-testing are highly accurate and of proven efficacy in directing therapy. We review MRD-testing technologies and evaluate the accuracy of MRD-testing for predicting relapse and the strength of evidence supporting efficacy of MRD-guided therapy. We show that at the individual level MRD-test results are often an inaccurate relapse predictor. Also, no convincing data indicate that increasing therapy-intensity based on a positive MRD-test reduces relapse risk or improves survival. We caution against adjusting therapy-intensity based solely on results of MRD-testing.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"68 ","pages":"Article 101226"},"PeriodicalIF":6.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142010021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH 在 PAH 和 CTEPH 采用多种药物疗法的时代，调整口服抗凝剂的治疗方法。
IF 6.9 2区 医学
Blood Reviews Pub Date : 2024-11-01 DOI: 10.1016/j.blre.2024.101240
Jean Escal , Geraldine Poenou , Xavier Delavenne , Souad Bezzeghoud , Valentine Mismetti , Marc Humbert , David Montani , Laurent Bertoletti
{"title":"Tailoring oral anticoagulant treatment in the era of multi-drug therapies for PAH and CTEPH","authors":"Jean Escal ,&nbsp;Geraldine Poenou ,&nbsp;Xavier Delavenne ,&nbsp;Souad Bezzeghoud ,&nbsp;Valentine Mismetti ,&nbsp;Marc Humbert ,&nbsp;David Montani ,&nbsp;Laurent Bertoletti","doi":"10.1016/j.blre.2024.101240","DOIUrl":"10.1016/j.blre.2024.101240","url":null,"abstract":"<div><div>The use of oral anticoagulants in the management of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) presents distinct therapeutic challenges and benefits. In PAH, the benefits of oral anticoagulation are uncertain, with studies yielding mixed results on their efficacy and safety. Conversely, oral anticoagulants are a cornerstone in the treatment of CTEPH, where their use is consistently recommended to prevent recurrent thromboembolic events. The choice between vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) remains a significant clinical question, as each type presents advantages and potential drawbacks. Furthermore, drug-drug interactions (DDIs) with concomitant PAH and CTEPH treatments complicate anticoagulant management, necessitating careful consideration of individual patient regimens. This review examines the current evidence on oral anticoagulant use in PAH and CTEPH and discusses the implications of DDIs within a context of multi-drug treatments, including targeted drugs in PAH.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"68 ","pages":"Article 101240"},"PeriodicalIF":6.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142156777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future 血液恶性肿瘤中循环肿瘤 DNA 的临床应用：从过去到未来
IF 6.9 2区 医学
Blood Reviews Pub Date : 2024-11-01 DOI: 10.1016/j.blre.2024.101237
Jun-Ying Li, Li-Ping Zuo, Jian Xu, Chun-Yan Sun
{"title":"Clinical applications of circulating tumor DNA in hematological malignancies: From past to the future","authors":"Jun-Ying Li,&nbsp;Li-Ping Zuo,&nbsp;Jian Xu,&nbsp;Chun-Yan Sun","doi":"10.1016/j.blre.2024.101237","DOIUrl":"10.1016/j.blre.2024.101237","url":null,"abstract":"<div><div>Liquid biopsy, particularly circulating tumor DNA (ctDNA), has drawn a lot of attention as a non- or minimal-invasive detection approach for clinical applications in patients with cancer. Many hematological malignancies are well suited for serial and repeated ctDNA surveillance due to relatively high ctDNA concentrations and high loads of tumor-specific genetic and epigenetic abnormalities. Progress of detecting technology in recent years has improved sensitivity and specificity significantly, thus broadening and strengthening the potential utilities of ctDNA including early diagnosis, prognosis estimation, treatment response evaluation, minimal residual disease monitoring, targeted therapy selection, and immunotherapy surveillance. This manuscript reviews the detection methodologies, clinical application and future challenges of ctDNA in hematological malignancies, especially for lymphomas, myeloma and leukemias.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"68 ","pages":"Article 101237"},"PeriodicalIF":6.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142252509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Longitudinal clinical manifestations of Fanconi anemia: A systematized review 范可尼贫血的纵向临床表现：系统回顾
IF 6.9 2区 医学
Blood Reviews Pub Date : 2024-11-01 DOI: 10.1016/j.blre.2024.101225
Alex Hoover , Lucie M. Turcotte , Rachel Phelan , Crystal Barbus , Arpana Rayannavar , Bradley S. Miller , Erin E. Reardon , Nicole Theis-Mahon , Margaret L. MacMillan
{"title":"Longitudinal clinical manifestations of Fanconi anemia: A systematized review","authors":"Alex Hoover ,&nbsp;Lucie M. Turcotte ,&nbsp;Rachel Phelan ,&nbsp;Crystal Barbus ,&nbsp;Arpana Rayannavar ,&nbsp;Bradley S. Miller ,&nbsp;Erin E. Reardon ,&nbsp;Nicole Theis-Mahon ,&nbsp;Margaret L. MacMillan","doi":"10.1016/j.blre.2024.101225","DOIUrl":"10.1016/j.blre.2024.101225","url":null,"abstract":"<div><div>Fanconi anemia (FA) is a rare and complex inherited genetic disorder characterized by impaired DNA repair mechanisms leading to genomic instability. Individuals with FA have increased susceptibility to congenital anomalies, progressive bone marrow failure, leukemia and malignant tumors, endocrinopathies and other medical issues. In recent decades, steadily improved approaches to hematopoietic cell transplantation (HCT), the only proven curative therapy for the hematologic manifestations of FA, have significantly increased the life expectancy of affected individuals, illuminating the need to understand the long-term consequences and multi-organ ramifications. Utilizing a systematized review approach with narrative synthesis of each primary issue and organ system, we shed light on the challenges and opportunities for optimizing the care and quality of life for individuals with FA and identify knowledge gaps informing future research directions.</div></div>","PeriodicalId":56139,"journal":{"name":"Blood Reviews","volume":"68 ","pages":"Article 101225"},"PeriodicalIF":6.9,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141899019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信